Exploring the feasibility of bacteriocins EntK1 and EntEJ97s in treatment of systemic vancomycin resistant enterococci infections in mice
Journal of Applied Microbiology · 2024
DOI: 10.1093/jambio/lxae054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Microbiology, 2024. Verfasst von Ingvild Reinseth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003 1432 Ås, Norway. Hauptthemen laut MEDLINE: Bacteriocins, Vancomycin-Resistant Enterococci, Enterococcus faecium, Bacterial Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway.
Abstract (Originalsprache)
Aims
Enterocins K1 and EJ97 have specific antimicrobial activity against Enterococcus faecium and Enterococcus faecalis, respectively. The aim of this study was to investigate the utility of these enterocins for in vivo treatment of systemic enterococcal infections. Methods and results The antimicrobial effect in blood was analysed and compared against the effect in saline. Colony forming unit counts revealed that the enterocins killed all the bacteria within 1 hour. Additionally, the bactericidal effect against E. faecalis was more rapid in blood, indicating a possible synergy between EntEJ97 and blood. Importantly, no enterocin resistant mutants emerged in these experiments. Injecting the enterocins intraperitoneally in an in vivo mouse model and using fluorescence and minimum inhibitory concentration determination to estimate concentrations of the peptides in plasma, indicate that the enterocins exist in circulation in therapeutic concentrations. Alanine aminotransferase detection, and haemolysis analysis indicates that there is no detectable liver damage or haemolytic effect after injection.
Conclusions
The study revealed that EntK1 and EntEJ97 are able to kill all bacteria ex vivo in the presence of blood. In vivo experiments determine that the enterocins exist in circulation in therapeutic concentrations without causing liver damage or haemolysis. Future experiments should test these peptides for treatment of infection in a relevant in vivo model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003 1432 Ås, Norway.
- Section of Pharmaceutics and Social Pharmacy, Department of Pharmacy, University of Oslo, P.O. Box 1068 Blindern 0316 Oslo, Norway.
ORCID-Profile: Ingvild Reinseth, Morten Kjos, Harald Carlsen
Förderung
- Research Council of Norway
Zitieren
APA
Reinseth, I., Diep, D. B., Kjos, M., Tønnesen, H. H., & Carlsen, H. (2024). Exploring the feasibility of bacteriocins EntK1 and EntEJ97s in treatment of systemic vancomycin resistant enterococci infections in mice. Journal of Applied Microbiology. https://doi.org/10.1093/jambio/lxae054
Vancouver
Reinseth I, Diep DB, Kjos M, Tønnesen HH, Carlsen H. Exploring the feasibility of bacteriocins EntK1 and EntEJ97s in treatment of systemic vancomycin resistant enterococci infections in mice. Journal of Applied Microbiology. 2024. doi:10.1093/jambio/lxae054
BibTeX
@article{Reinseth2024,
author = {Reinseth, Ingvild and Diep, Dzung B and Kjos, Morten and Tønnesen, Hanne H and Carlsen, Harald},
title = {Exploring the feasibility of bacteriocins EntK1 and EntEJ97s in treatment of systemic vancomycin resistant enterococci infections in mice},
journal = {Journal of Applied Microbiology},
year = {2024},
doi = {10.1093/jambio/lxae054}
}
EUVIMED